down arrow

Synlogic, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US87166L2097
USD
1.15
-0.27 (-19.01%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.101.33

52 Week

0.901.96
Valuation
Technical
Day's Volume

CASH

731.74 k

Shareholding (Mar 2025)

FII

0.24%

Held by 5 FIIs

DII

64.06%

Held by 6 DIIs

Promoter

30.38%

How big is Synlogic, Inc.?

22-Jun-2025

As of Jun 18, Synlogic, Inc. has a market capitalization of 14.50 million, categorizing it as a Micro Cap company, with shareholder's funds of 12.75 million and total assets of 19.83 million as of December 2024.

Market Cap: As of Jun 18, Synlogic, Inc. has a market capitalization of 14.50 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters ending in March 2025, December 2024, September 2024, and June 2024, Synlogic, Inc. reported net sales of 0.00 million and a net profit of 1.50 million.<BR><BR>Balance Sheet Snapshot: As of December 2024, the company reported shareholder's funds of 12.75 million and total assets of 19.83 million.

Read More

What does Synlogic, Inc. do?

22-Jun-2025

Synlogic, Inc. develops Synthetic Biotic medicines for rare genetic diseases and operates in the micro-cap Pharmaceuticals & Biotechnology sector, with a market cap of $14.50 million. The company is currently loss-making, with no dividend yield and negative return on equity.

Overview:<BR>Synlogic, Inc. is engaged in the development of Synthetic Biotic medicines for the treatment of rare genetic diseases and other conditions within the Pharmaceuticals & Biotechnology industry, operating in the micro-cap market.<BR><BR>Financial Snapshot:<BR>- Most recent Net Profit: 0 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 14.50 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -1.32<BR>- Return on Equity: -38.28%<BR>- Price to Book: 1.11<BR><BR>Contact Details:<BR>- Address: 301 Binney St Ste 402, CAMBRIDGE MA: 02142-1030<BR>- Tel: 1 617 4019975<BR>- Website: https://www.synlogictx.com/

Read More

Who are in the management team of Synlogic, Inc.?

22-Jun-2025

As of March 2022, the management team of Synlogic, Inc. includes Dr. Peter Barrett (Independent Chairman), Dr. Aoife Brennan (CEO), and several independent directors: Mr. Michael Heffernan, Dr. Michael Burgess, Dr. Patricia Hurter, Mr. Chau Khuong, and Mr. Nick Leschly. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Synlogic, Inc. includes the following individuals:<BR><BR>- Dr. Peter Barrett, Independent Chairman of the Board<BR>- Dr. Aoife Brennan, President, Chief Executive Officer, Director<BR>- Mr. Michael Heffernan, Director<BR>- Dr. Michael Burgess, Independent Director<BR>- Dr. Patricia Hurter, Independent Director<BR>- Mr. Chau Khuong, Independent Director<BR>- Mr. Nick Leschly, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Read More

Is Synlogic, Inc. overvalued or undervalued?

25-Jun-2025

As of March 6, 2025, Synlogic, Inc. is considered overvalued and has been downgraded to "does not qualify" due to unfavorable financial metrics and poor stock performance compared to its peers and the S&P 500.

As of 6 March 2025, Synlogic, Inc. has moved from a grade of risky to does not qualify, indicating a significant downgrade in its valuation outlook. The company is currently assessed as overvalued given its financial metrics, including a Price to Book Value of 1.08, an EV to EBIT of 0.51, and an ROCE of 145.50%, despite reporting a negative ROE of -38.28%. <BR><BR>In comparison to its peers, Synlogic is positioned unfavorably against Poseida Therapeutics, Inc., which has a P/E of -15.24, and Xeris Biopharma Holdings, Inc., with a P/E of -15.77, both of which are also categorized as risky. The company's recent stock performance has underperformed the S&P 500, with a year-to-date return of -16.43% compared to the S&P 500's 2.44%. This combination of factors suggests that Synlogic, Inc. is overvalued in the current market environment.

Read More

Is Synlogic, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, Synlogic, Inc. shows a bullish trend with positive momentum indicators, though it has underperformed in the long term despite recent outperformance against the S&P 500.

As of 2 September 2025, the technical trend for Synlogic, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, indicating positive momentum. The daily moving averages are also bullish. However, the monthly Dow Theory remains bearish, and the OBV shows mild bearishness on a monthly basis. <BR><BR>In terms of performance, Synlogic has outperformed the S&P 500 in the past week (13.61% vs. 1.05%) and the past month (16.78% vs. 2.33%), but it has significantly underperformed over longer periods, particularly in the 3-year and 5-year returns. Overall, the current stance is bullish, but with some mixed signals in the longer-term indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 17 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.35

stock-summary
Return on Equity

-20.98%

stock-summary
Price to Book

1.37

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-22.82%
0%
-22.82%
6 Months
-1.71%
0%
-1.71%
1 Year
-17.86%
0%
-17.86%
2 Years
-55.08%
0%
-55.08%
3 Years
45.75%
0%
45.75%
4 Years
-96.62%
0%
-96.62%
5 Years
-96.79%
0%
-96.79%

Synlogic, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Synlogic, Inc. technically bullish or bearish?

As of 2 September 2025, the technical trend for Synlogic, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, indicating positive momentum. The daily moving averages are also bullish. However, the monthly Dow Theory remains bearish, and the OBV shows mild bearishness on a monthly basis. In terms of performance, Synlogic has outperformed the S&P 500 in the past week (13.61% vs. 1.05%) and the past month (16.78% vs. 2.33%), but it has significantly underperformed over longer periods, particularly in the 3-year and 5-year returns. Overall, the current stance is bullish, but with some mixed signals in the longer-term indicators....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
14.19%
EBIT to Interest (avg)
-48.81
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.32
Sales to Capital Employed (avg)
0.09
Tax Ratio
0.33%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
74.51%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.08
EV to EBIT
0.51
EV to EBITDA
0.51
EV to Capital Employed
0.74
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
145.50%
ROE (Latest)
-38.28%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 9 Schemes (5.32%)

Foreign Institutions

Held by 5 Foreign Institutions (0.24%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -266.67% vs 142.86% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.80",
          "val2": "-0.90",
          "chgp": "11.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "1.00",
          "chgp": "-90.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.50",
          "val2": "0.30",
          "chgp": "-266.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs 183.33% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 59.16% vs 13.31% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "3.40",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.50",
          "val2": "-49.90",
          "chgp": "70.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-9.00",
          "val2": "-4.10",
          "chgp": "-119.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-23.40",
          "val2": "-57.30",
          "chgp": "59.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,972,125.00%",
          "val2": "-16,363.40%",
          "chgp": "-1,95,576.16%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.80
-0.90
11.11%
Interest
0.00
0.00
Exceptional Items
0.10
1.00
-90.00%
Consolidate Net Profit
-0.50
0.30
-266.67%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -266.67% vs 142.86% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
3.40
-100.00%
Operating Profit (PBDIT) excl Other Income
-14.50
-49.90
70.94%
Interest
0.00
0.00
Exceptional Items
-9.00
-4.10
-119.51%
Consolidate Net Profit
-23.40
-57.30
59.16%
Operating Profit Margin (Excl OI)
-1,972,125.00%
-16,363.40%
-1,95,576.16%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs 183.33% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 59.16% vs 13.31% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Synlogic, Inc. stock-summary
stock-summary
Synlogic, Inc.
Pharmaceuticals & Biotechnology
Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.
Company Coordinates stock-summary
Company Details
301 Binney St Ste 402 , CAMBRIDGE MA : 02142-1030
stock-summary
Tel: 1 617 4019975
stock-summary
https://www.synlogictx.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."